INVESTOR PROFILE

Vesalius Biocapital III

Vesalius Biocapital III

Vesalius Biocapital III

Luxembourg

Vesalius Biocapital III is a €70 million fund that invests in medtech, e-health initiatives and drug development in Europe. It was launched in 2017 by Luxembourg-based Vesalius Biocapital, a life sciences venture capital firm founded in 2007.  Preceding Vesalius Biocapital III were Vesalius Biocapital I, with €76 million under management and Vesalius Biocapital II, which has €78 million invested; both funds have 11 portfolio companies each. Its recent investments include in Portuguese home physiotherapy tech solution SWORD Health's 2021 $25m Series B and in the 2020 $9m second phase of its Series A round as well as in the 2020 €22m Series B round of German biotech Topas Therapeutics. 

The rest of the content is exclusive to Premium subscribers

Subscribe now to continue accessing our full range of insights and data.

I’m a/an
  • Entreprenuer
  • Investors
  • Researcher
  • Technology & Startup Enthusiast
  • Government Staff

Your payment was not successful.

Please make sure you have entered your payment details correctly. Or try again in a few moments.

small logo

The discount code you entered is invalid

Please make sure you have entered your discount code correctly. Or try again in a few moments.

Download successful.

Your sample has been sent. Please check your email.

By continuing to browse this website, you consent to our use of cookies, as well as to our Terms of Use and Privacy Policy which provide additional information about how we process your data. This website uses cookies to enhance your user experience. Please read our Cookies Policy for more information on how we use cookies, as well as instructions on how to disable cookies. You may disable cookies through your internet browser settings, however this may result in some parts of the website not working properly for you.